Preventive gynecology: attitude and practice among gynecologists of Central Kerala

Radha K. R., Reena R. P., Jacob K. J.


Background: Carcinoma breast and carcinoma cervix are leading causes for cancer deaths in India. However, they get detected only in late stages of the disease. Preventive measures and early detection of disease will decrease the burden from these cancers. We evaluated the strategies followed by practising gynaecologists of Central Kerala to reduce this burden.

Methods: A survey was conducted among 270 practising gynaecologists of Central Kerala, using a questionnaire. This evaluated implementation of screening and preventive measures used by them for self-protection as well as for the women seeking their services. Their attitude regarding HPV vaccine as a preventive measure was also noted.

Results: Pap smear was done by only 84(32.8%) out of 256 gynaecologists or their spouses. Routine Pap smear was recommended by 60.5% of private practitioners and 84% of government practitioners. Counselling regarding the HPV vaccine was offered to young women by 37.8% of gynaecologists only. Use of HPV vaccine for their daughters was also quite infrequent (24.1%).

Conclusions: The utilization of existing preventive strategies and measures for early detection of premalignant and malignant lesions is far from optimum. There is a need to step up in service training and continuing medical education for health care personnel in this direction.


Cervical cancer, HPV vaccine, Mammography, Pap smear

Full Text:



WHO Cancer country profile 2014 prepared by IACR. Available from:

Nandakumar A, Anantha N, Venugopal TC. Incidence, mortality and survival in cancer of the cervix in Bangalore, India. Br J Cancer. 1995;71(6):1348-52.

Grulich AE, Jin F, Conway EL, Stein AN, Hocking J. Cancers attributable to human papilloma virus infection. Sex Health. 2010;7(3):244-52.

de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11:1048-5.

Sasieni P, Castanon A, Cuzick J. Effectiveness of cervical screening with age: population based case control study of prospectively recorded data. BMJ 2009;339:b2968.

Central Intelligence Agency – The World Factbook. Available from:

Final Report of the Committee appointed by the Govt. of India, vide notification No. V.25011/160/2010-HR dated 15th April, 2010, to enquire into Alleged irregularities in the conduct of studies using Human Papilloma Virus (HPV) vaccine by PATH in India February 15, 2011.

Radha KR, Reena RP. Factors associated with delayed reporting of invasive carcinoma Obstetrics cervix in a rural tertiary care centre. J Obstet Gynaecol India. 2016;66(5):S417-S421.

McRee AL, Gilkey MB, Dempsey AF. HPV vaccine hesitancy: findings from a statewide survey of health care providers. J Pediatr Health Care. 2014;28(6):541-9.

Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2009;151:716-26.

Kay M, Mitchell G, Del Mar C. Doctors do not look after their own physical health. Med J Aust. 2004;181(7):368-70.

Aswathy S, Quereshi MA, Kurian B, Leelamoni K. Cervical cancer screening: Current knowledge and practice among women in a rural population of Kerala, India. Indian J Med Res. 2012;136(2):205-10.

Catarino R, Petignat P, Dongui G, Vassilakos P. Cervical cancer screening in developing countries at a crossroad: Emerging technologies and policy choices. World J Clin Oncol. 2015;6:281-90.

Sasieni P, Castanon A, Cuzick J. Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data. BMJ. 2009;339:b2968.

Future II study group, Quadrivalent vaccine against Human Papilloma virus to prevent high grade cervical lesion. New Engl J Med. 2007;356(19):1915-27.

Apter D, Wheeler CM, Paavonen J, Castellsagué X, Garland SM, Skinner SR, Naud P, Salmerón J, Chow SN, Kitchener HC, Teixeira JC. Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial. Clini Vaccine Immunol. 2015;22(4):361-73.

Markowitz LE, Dunne EF, Saraiya M, Chesson HW, Curtis CR, Gee J et al. Human Papillomavirus Vaccination Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Reports. 2014;63(1):1-30.

Markowitz LE, Hariri S, Lin C, Dunne EF, Steinau M, McQuillan G et al. Unger Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010. J Infect Dis. 2013;208(3):385-93.

Van de Velde N, Boily MC, Drolet M, Franco EL, Mayrand MH, Kliewer EV et al. Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis. J Natl Cancer Inst. 2012;104:1712-23.

WHO /Global Advisory Committee on Vaccine safety Statement on Safety of HPV vaccines 17 December 2015.